APO GLYBURIDE TAB 5MG 5 MG
GLYBURIDE : 5 MG · DIN 01913662 · APOTEX INC
Health Canada status: MARKETED
What is APO GLYBURIDE TAB 5MG?
APO GLYBURIDE TAB 5MG 5 MG contains GLYBURIDE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 01913662, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1991. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01913662 |
|---|---|
| Brand name | APO GLYBURIDE TAB 5MG |
| Generic / active ingredient | GLYBURIDE : 5 MG |
| Manufacturer | APOTEX INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BB01 GLIBENCLAMIDE |
| AHFS class | 68:20.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1991 |
| Original market date | 1991-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A10BB01 GLIBENCLAMIDE. 4 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO GLYBURIDE TAB 2.5MG | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 01913654 |
| TEVA-GLYBURIDE | 2.5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01913670 |
| TEVA-GLYBURIDE | 5 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 01913689 |
| AVA-GLYBURIDE | 2.5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363704 |
| AVA-GLYBURIDE | 5 MG | TABLET | AVANSTRA INC | CANCELLED POST MARKET | DIN 02363712 |
| DIABETA | 2.5 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02224550 |
| DIABETA | 5 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 02224569 |
| DIABETA 5MG | 5 MG | TABLET | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00012599 |
| DIABETA TAB 2.5MG | 2.5 MG | TABLET | HOECHST CANADA INC. | CANCELLED POST MARKET | DIN 00454753 |
| DIABETA TAB 5MG | 5 MG | TABLET | HOECHST ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 01987836 |
Who else supplies GLIBENCLAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLIBENCLAMIDE appears in 37 registered pack listings across 7 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.